Biotech and Pharmaceuticals Pharmaceuticals

  • Traders applied the brakes Thursday, a day after the Dow topped 10,000, as Goldman Sachs and Citigroup proved no match for Wall Street's inflated earnings expectations.

  • Stocks pared their losses Thursday after a third straight positive Philly Fed reading — the first time that's happened in two years.  Stocks had opened lower after disappointment in earnings from Goldman Sachs and Citigroup.

  • After Wednesday's stellar market performance, stock index futures indicated a lower open for Wall Street on Thursday as investors take a breather and evaluate their next move.

  • dow_10K_cnbc2_200.jpg

    Stocks rallied Wednesday and the Dow broke through 10,000 for the first time in over a year, fueled by strong earnings from JPMorgan and Intel.

  • swine_flu_needle_200.jpg

    This Friday the CDC is expected to start giving weekly updates on where and how much H1N1 vaccine has been shipped. I'm curious what the demand will truly turn out to be. Some people are growing concerned about the increasing number of pediatric deaths from H1N1 and may rush to get their kids and themselves vaccinated. Others are afraid of or paranoid about the vaccine.

  • Stocks rallied Wednesday, with the Dow homing in on 10,000, after JPMorgan and Intel got earnings season back on track and retail sales fell less than expected.

  • Futures pointed to a strong open Wednesday, with the Dow ready to make another run at 10,000, after JPMorgan and Intel got earnings season back on track and retail sales fell less than expected.

  • Novartis Headquarters

    Vanda Pharmaceuticals may go down in industry history as one of the most remarkable turnaround stories.

  • Dow component Johnson & Johnson—the first major health care company to report earnings this quarter—posted weaker-than-expected quarterly revenue on Tuesday. Mike Weinstein, managing director and senior medical technology analyst at JPMorgan, offered his analysis of JNJ.

  • Stocks fell on Tuesday after the Dow closed near the 10,000 mark on Monday. What is the best move for investors now? Roy Williams, CEO of Prestige Wealth Management, and Bill Smead, CEO and CIO of Smead Capital Management, shared their investment insights.

  • Dendreon is growing in more ways than one. At a time when so many drug companies are letting people go, Dendreon is on a hiring binge to ramp up for the anticipated launch of its prostate cancer drug Provenge. But it's also expanding its board of directors.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    A “ton of upside” is in store for this stock, Cramer says. Find out why.

  • MM_promo_Cramerica_Challenge_530x50.jpg

    It’s all about the earnings, he says. These are the companies you need to watch.

  • With $137 billion worth of brand name drugs going generic over the next several years, the recession and the looming threat of healthcare reform a lot of people have been running scared about what it all means for pharma. So, surprise, surprise! This morning IMS Health, which closely monitors the industry, came out with its annual forecast and it now says the American drug market is going to grow this year instead of shrink.

  • rats_200.jpg

    I’ve said it before, and I know it’s a bad cliché (is there such a thing as a good cliché?), but I learn something new almost every day. Today, my lesson came in the form of an eye-catching research note out of Leerink Swann, which specializes in covering healthcare-related companies and stocks.

  • Pharmacist wearing face mask

    Yesterday and today thousands of kids and healthcare workers around the country started getting AstraZeneca's H1N1 FluMist, the vaccine that's sprayed into the nose. The first shots from Novartis and Sanofi-Aventis may be available later this week. GlaxoSmithKline and Baxter are still waiting for the FDA to approve their vaccines.

  • Stocks rebounded Monday as investors' waning enthusiasm got a jolt from a report that showed the services sector has begun to expand. Plus, there was some bargain hunting after the market's two-week decline.

  • Stocks rebounded Monday as investors' waning enthusiasm got a jolt from a report that showed the services sector has begun to expand. Plus, there was some bargain hunting after the market's two-week decline.

  • Stocks advanced Monday after a better-than-expected reading on the service sector. Plus, investors did some bargain hunting after a two-week decline.

  • If you were ever needed examples of the phenomenal risk and reward of investing in baby biopharma look no further than what’s going on in the sector today.